Pulsethera, Inc.
Developer of a phototherapy platform that uses blue light (410–460 nm) to photoinactivate microbial catalase, increasing susceptibility of catalase-positive bacteria and fungi to reactive oxygen species and ROS-generating agents. The organisation has published preclinical in vitro and in vivo data, holds issued US patents with additional international filings pending, has received NIH funding for related research, and is preparing regulatory interactions in the United States.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
Phototherapy for wound infections and ulcers
Development of a blue-light phototherapy approach combined with ROS-generating agents to treat infected wounds, including diabetic foot ulcers and pressure ulcers.
Phototherapy for acne vulgaris
Blue-light–based phototherapy developed to kill Cutibacterium acnes in combination with benzoyl peroxide.
Phototherapy for fungal skin colonization and infection
Phototherapy approaches intended to sensitize Candida spp. to hydrogen peroxide and other ROS-producing agents; demonstrated in vitro activity against Candida species including C. auris and C. albicans.
Platform for surface-based infection control
Development of photonic technology for inanimate surface disinfection to reduce surface-mediated transmission of catalase-positive microbes.
Phototherapy for wound infections and ulcers
Development of a blue-light phototherapy approach combined with ROS-generating agents to treat infected wounds, including diabetic foot ulcers and pressure ulcers.
Phototherapy for acne vulgaris
Blue-light–based phototherapy developed to kill Cutibacterium acnes in combination with benzoyl peroxide.
Phototherapy for fungal skin colonization and infection
Phototherapy approaches intended to sensitize Candida spp. to hydrogen peroxide and other ROS-producing agents; demonstrated in vitro activity against Candida species including C. auris and C. albicans.
Platform for surface-based infection control
Development of photonic technology for inanimate surface disinfection to reduce surface-mediated transmission of catalase-positive microbes.
Expertise Areas
- Phototherapy for antimicrobial applications
- Preclinical infectious-disease research
- Wound-care therapeutics development
- Surface disinfection and decontamination
Key Technologies
- Blue-light phototherapy (410–460 nm)
- Photoinactivation of catalase
- ROS-sensitization strategies
- Combination therapy with hydrogen peroxide and ROS-generating agents
News & Updates
Peer-reviewed article reporting that catalase can be inactivated by blue light, rendering Candida species more susceptible to hydrogen peroxide and ROS-producing agents.
Article describing research using phototherapy combined with hydrogen peroxide to kill antibiotic-resistant bacteria.
News article summarizing research on blue-light effects against MRSA.
Peer-reviewed article reporting that catalase can be inactivated by blue light, rendering Candida species more susceptible to hydrogen peroxide and ROS-producing agents.
Article describing research using phototherapy combined with hydrogen peroxide to kill antibiotic-resistant bacteria.
News article summarizing research on blue-light effects against MRSA.